Back to Journals » Therapeutics and Clinical Risk Management » Volume 14

Pre-treatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy

Authors Kamimura M, Taguchi A, Nakamura Y, Koiwai H, Ikegami S, Uchiyama S, Kato H

Received 20 October 2017

Accepted for publication 13 December 2017

Published 3 April 2018 Volume 2018:14 Pages 637—642

DOI https://doi.org/10.2147/TCRM.S154686

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Hoa Le

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh


Mikio Kamimura,1 Akira Taguchi,2 Yukio Nakamura,3,4 Hidefumi Koiwai,5 Shota Ikegami,3 Shigeharu Uchiyama,3 Hiroyuki Kato3

1Center for Osteoporosis and Spinal Disorders, Kamimura Orthopedic Clinic, Matsumoto, Japan; 2Department of Oral and Maxillofacial Radiology, Matsumoto Dental University, Shiojiri, Japan; 3Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan; 4Department of Orthopedic Surgery, Showa-Inan General Hospital, Komagane, Japan; 5Koiwai Orthopedic Clinic, Komoro, Japan

Background: While it is well known that teriparatide (TPTD) increases bone mineral density (BMD) in osteoporotic patients, it is unknown whether TPTD pretreatment affects BMD after denosumab (DMAb) therapy.
Methods: Fifty-seven patients in TPTD-pretreated group and 35 patients in DMAb-alone group had been further analyzed, all of whom were treated by DMAb for 1.5 years. Vitamin D (400 IU) and Ca (600 mg) supplementation was used in all patients. The BMD of lumbar 1–4 vertebrae (L-BMD), bilateral total hips (H-BMD), and bilateral femoral neck (FN-BMD) was quantified at first visit, and at 4, 8, 12, and 18 months after daily TPTD treatment following four times DMAb treatment.
Results: There were significant differences in L-BMD (p=0.004) and H-BMD (p=0.026) at baseline between TPTD-pretreated and DMAb-alone groups, although there was no significant difference in FN-BMD between the two groups. The increase of L-BMD by DMAb therapy was less in TPTD-pretreated group than in DMAb-alone group. There was no significant difference in H-BMD, although percent changes of H-BMD tended to be higher in the TPTD-pretreated group than those in the DMAb-alone group. Percent change in FN-BMD at 4 months (p=0.067) and 12 months (p=0.057) tended to be higher in TPTD-pretreated group than in DMAb-alone group. Percent change in FN-BMD at 18 months was significantly higher in TPTD-pretreated group (p=0.004) than in DMAb-alone group.
Conclusion: These findings suggest that the pretreatment of TPTD might have enhanced the increase of BMD in cortical bones treated by DMAb. Thus, it is favorable that TPTD can be used for osteoporotic patients who have high fracture risks with cortical bones.

Keywords: bone mineral density, cancelleous bones, cortical bone, daily teriparatide, denosumab, osteoporosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]